| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Frequency Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.98 |
| 52 Week High | US$279.50 |
| 52 Week Low | US$9.15 |
| Beta | 0.77 |
| 1 Month Change | -0.10% |
| 3 Month Change | -58.68% |
| 1 Year Change | -87.52% |
| 3 Year Change | -98.71% |
| 5 Year Change | n/a |
| Change since IPO | -97.81% |
Recent News & Updates
Recent updates
Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?
Jan 01
Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?
Jan 19Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year
Aug 18Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?
Jul 31Frequency Therapeutics (FREQ) Investor Presentation - Slideshow
Jun 18Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout
Apr 21Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be
Apr 04We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn
Mar 15If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns
Jan 22Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?
Dec 27Frequency Therapeutics to host investor event in early January next year
Dec 18How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?
Dec 10Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 19Frequency Therapeutics EPS beats by $0.16, beats on revenue
Nov 16Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
Nov 09Shareholder Returns
| FREQ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 29.1% | 1.0% | 1.2% |
| 1Y | -87.5% | 0.7% | 24.9% |
Return vs Industry: FREQ underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: FREQ underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| FREQ volatility | |
|---|---|
| FREQ Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FREQ's share price has been volatile over the past 3 months.
Volatility Over Time: FREQ's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 47 | David Lucchino | www.frequencytx.com |
As of November 3, 2023, Frequency Therapeutics, Inc. was acquired by Korro Bio, Inc., in a reverse merger transaction. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person’s innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue.
Frequency Therapeutics, Inc. Fundamentals Summary
| FREQ fundamental statistics | |
|---|---|
| Market cap | US$547.27m |
| Earnings (TTM) | -US$59.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.2x
P/E RatioIs FREQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FREQ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$42.02m |
| Gross Profit | -US$42.01m |
| Other Expenses | US$17.30m |
| Earnings | -US$59.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did FREQ perform over the long term?
See historical performance and comparison